Aquilo Capital Management

Aquilo concentrates almost entirely on the biotechnology and life sciences sectors. The firm invests in both publicly traded biotech companies and private, venture-stage therapeutics developers. Its investment process relies on internal, PhD-level scientific due diligence to assess clinical data, regulatory pathways, and competitive dynamics in areas such as oncology, rare diseases, and genetic medicine.

Aquilo does not publicly disclose its client base or capital structure. Its operational profile—with offices in San Francisco, New York, and London, and a specialist investment team—is consistent with a single-family office managing substantial principal capital, though some family office structures do accept select external co-investment relationships. No marketing or fundraising materials are publicly available.

The firm's San Francisco location provides direct proximity to the Bay Area's dense biotech startup ecosystem, suggesting access to venture deal flow before broader syndication. Aquilo's internal scientific team, rather than external sell-side analysts, conducts primary diligence on clinical trial data, FDA interactions, and competitive therapeutic landscapes, allowing the firm to form high-conviction views independently of market consensus.

Aquilo targets both publicly traded biotech companies and late-stage private therapeutics companies. In the public markets, it takes concentrated positions across market capitalizations in companies with near-term clinical catalysts. In private markets, it participates in crossover and venture financing rounds, often alongside top-tier biotech venture capital and crossover funds.

Aquilo's investment focus spans North America and Europe, with offices in San Francisco, New York, and London. The London presence is strategically positioned for sourcing and monitoring investments in the UK, Switzerland, and Scandinavian biotech clusters, which are among the world's most active for early-stage therapeutic innovation alongside the US.

The identity of Aquilo's principals and the origin of the firm's capital have not been publicly disclosed. The firm's singular focus on biotech suggests the founding principal may have a background in the life sciences industry—either through founding or executive roles at biotech or pharmaceutical companies—but this has not been confirmed by public records.

Aquilo does not diversify across sectors; it operates as a dedicated biotech specialist with an internal team of scientific professionals who conduct primary research typically sourced from academic journals, medical conferences, and direct company engagement. Unlike generalist healthcare funds, Aquilo's process centers on binary clinical-risk underwriting—evaluating individual drug candidates, trial designs, and regulatory outcomes—rather than on diversified sector exposure or systematic strategies.